CN111971091A - 预防或治疗骨髓发育不良综合征的抗bst1抗体 - Google Patents

预防或治疗骨髓发育不良综合征的抗bst1抗体 Download PDF

Info

Publication number
CN111971091A
CN111971091A CN201980025575.XA CN201980025575A CN111971091A CN 111971091 A CN111971091 A CN 111971091A CN 201980025575 A CN201980025575 A CN 201980025575A CN 111971091 A CN111971091 A CN 111971091A
Authority
CN
China
Prior art keywords
antibody
seq
antigen
bst1
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025575.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·贝拉罗萨
C·卡利斯
A·贝拉卡尼
C·罗尔弗
J·E·奥克罗伊德
M·比纳其
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Publication of CN111971091A publication Critical patent/CN111971091A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201980025575.XA 2018-04-13 2019-04-12 预防或治疗骨髓发育不良综合征的抗bst1抗体 Pending CN111971091A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1806084.8A GB201806084D0 (en) 2018-04-13 2018-04-13 Antibodies
GB1806084.8 2018-04-13
PCT/EP2019/059420 WO2019197609A1 (en) 2018-04-13 2019-04-12 Antibodies against bst1 for preventing or treating myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CN111971091A true CN111971091A (zh) 2020-11-20

Family

ID=62203296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025575.XA Pending CN111971091A (zh) 2018-04-13 2019-04-12 预防或治疗骨髓发育不良综合征的抗bst1抗体

Country Status (7)

Country Link
US (1) US20210032360A1 (https=)
EP (1) EP3773917A1 (https=)
JP (1) JP2021521201A (https=)
CN (1) CN111971091A (https=)
GB (1) GB201806084D0 (https=)
TW (1) TW201943732A (https=)
WO (1) WO2019197609A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132697A (zh) * 2017-07-21 2020-05-08 柏林化学股份公司 包含抗bst-1抗体和胞苷类似物的药物组合
CN112630438A (zh) * 2021-03-08 2021-04-09 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119301155A (zh) * 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295921A (ja) * 2004-04-14 2005-10-27 Pharma Design Inc 新規ｂｓｔ１選択的スプライシング変異体及びその用途
CN103261227A (zh) * 2010-10-04 2013-08-21 贝林格尔.英格海姆国际有限公司 Cd33结合剂
CN103649121A (zh) * 2011-06-28 2014-03-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295921A (ja) * 2004-04-14 2005-10-27 Pharma Design Inc 新規ｂｓｔ１選択的スプライシング変異体及びその用途
CN103261227A (zh) * 2010-10-04 2013-08-21 贝林格尔.英格海姆国际有限公司 Cd33结合剂
CN103649121A (zh) * 2011-06-28 2014-03-19 牛津生物疗法有限公司 针对adp-核糖基环化酶2的抗体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132697A (zh) * 2017-07-21 2020-05-08 柏林化学股份公司 包含抗bst-1抗体和胞苷类似物的药物组合
CN112630438A (zh) * 2021-03-08 2021-04-09 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用

Also Published As

Publication number Publication date
US20210032360A1 (en) 2021-02-04
WO2019197609A1 (en) 2019-10-17
TW201943732A (zh) 2019-11-16
JP2021521201A (ja) 2021-08-26
EP3773917A1 (en) 2021-02-17
GB201806084D0 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
AU2014203781B2 (en) Antibodies specific to Cadherin-17
CN103534268B (zh) 抗体
KR102058185B1 (ko) Adp-리보실 시클라제 2에 대한 항체
CN111971091A (zh) 预防或治疗骨髓发育不良综合征的抗bst1抗体
US20200231694A1 (en) Pharmaceutical combinations comprising an anti-bst-1 antibody and a cytidine analogue
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201120